AbCellera Biologics (ABCL) Pivots to Clinical Stage as 2025 Revenue Hits $75M

Maham Fatima

Fri, February 27, 2026 at 4:28 AM GMT+9 2 min read

In this article:

ABCL

+7.82%

AbCellera Biologics Inc. (NASDAQ:ABCL) is one of the most promising penny stocks under $5 to buy. On February 24, AbCellera Biologics announced its Q4 and full-year 2025 financial results, marking a major transition into a clinical-stage biotechnology company. The firm ended the year with $75 million in total revenue, which was composed of $27 million from partnered programs and $48 million from licensing and royalties, while reporting a net loss of $146 million.

This loss reflects a significant pivot toward internal pipeline development, as evidenced by a $187 million investment in R&D. The company’s clinical pipeline saw substantial progress in 2025, highlighted by the advancement of its lead program, ABCL635, into Phase 2 studies for vasomotor symptoms/VMS. Encouraging target engagement data has notably increased the estimated probability of success for this program, with a major readout expected in the third quarter of 2026.

AbCellera Biologics (ABCL) Pivots to Clinical Stage as 2025 Revenue Hits $75M

Additionally, the company’s second lead program, ABCL575, is currently in Phase 1 trials with data anticipated by year-end. To support this expanding portfolio, AbCellera has nearly completed its own clinical manufacturing facility, providing greater control over its supply chain and proprietary technology. While AbCellera Biologics Inc. (NASDAQ:ABCL) is reducing transparency on partner-initiated program starts by moving to less frequent reporting, it remains focused on internal first-in-class programs in oncology and immunology.

AbCellera Biologics Inc. (NASDAQ:ABCL) discovers and develops antibody-based medicines for indications with unmet medical needs in the US.

While we acknowledge the potential of ABCL as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. Follow Insider Monkey on Google News**.**

Terms and Privacy Policy

Privacy Dashboard

More Info